IBM’s “Watson” the Future of Cancer Prognosis Tools?
Based on this background information, Watson is able to boast an 83% overall accuracy for its standard of care recommendations
While immunotherapy continues to dominate the discussion on #ASCO14, the use of IBM’s “Watson” is a smaller trending topic that deserves greater attention as we look toward the future of prognosis for various forms of cancer.
According to an article in ASCO Daily News, IBM’s “Watson” is an oncology computing system with three main functions for physicians based on up-to-date knowledge: a patient summary, treatment options, and a pathway advisory. The results of the functions are based on the evaluation of results from 400 historical patient cases. Based on this background information, Watson is able to boast an 83% overall accuracy for its standard of care recommendations. With oncologists’ increasing reliance on technology for access to up-to-date information, could Watson eventually become the go-to tool for cancer prognosis?